Technology | Atherectomy Devices | January 16, 2018

Medtronic Receives FDA Clearance for Riptide Aspiration System

New system expands neurovascular product portfolio for the treatment of acute ischemic stroke

Medtronic Receives FDA Clearance for Riptide Aspiration System

January 16, 2018 — Medtronic plc announced the company’s Neurovascular business unit received U.S. Food and Drug Administration (FDA) clearance of the Riptide Aspiration System, adding a tool to its acute ischemic stroke (AIS) product portfolio.

The Riptide Aspiration System is designed to retrieve thrombus (blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke. The procedure involves inserting a catheter through an incision in the leg and up to the blocked artery, allowing the physician to remove the blood clot.

The Riptide Aspiration System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar and vertebral arteries) within eight hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

“While I primarily use the Solitaire Revascularization Device to treat patients with acute ischemic stroke, I utilize a direct aspiration approach as my first-line treatment strategy in select circumstances such as basilar artery thromboembolism and in select anterior circulation cases,” said Daniel Sahlein, M.D., interventional neuroradiologist, Goodman Campbell Brain and Spine, assistant professor of clinical neurology in the Department of Neurological Surgery, Indianapolis University-Purdue University Indianapolis. “The Riptide Aspiration System will provide me with another proven Medtronic product to utilize when treating stroke patients.”

The Riptide Aspiration System includes the Arc Catheter, Riptide Aspiration Tubing, Riptide Aspiration Pump and Riptide Collection Canister with intermediate tubing. The Riptide Aspiration System is a foundational platform for future aspiration catheters, currently in development.

According to the American Heart Association/American Stroke Association (AHA/ASA), stroke is the fifth leading cause of death in the United States, and a leading cause of disability. In June 2015, the AHA/ASA published new stroke treatment guidelines that recommended the use of stent retriever technology – such as the Solitaire stent retriever device – in conjunction with IV rtPA/alteplase as a first-line treatment for eligible patients.

For more information: www.medtronic.com

 

Related Content

Avinger Receives FDA Clearance of Next-Generation Pantheris Device
Technology | Atherectomy Devices | May 24, 2018
Avinger Inc. announced that the company received 510(k) clearance from the U.S. Food & Drug Administration (FDA)...
Avinger Announces Treatment of First Patients With Next-Generation Pantheris
News | Atherectomy Devices | January 09, 2018
January 9, 2018 – Avinger Inc. announced that Arne Schwindt, M.D., a vascular surgeon at St.
Avinger Receives 510(k) Clearance for Pantheris Image-Guided Atherectomy Device Modifications
Technology | Atherectomy Devices | November 20, 2017
November 20, 2017 — Avinger Inc. announced in October that the company received 510(k) clearance from the U.S.
Avinger Receives CE Mark for In-Stent Restenosis Indication With Pantheris Image-Guided Atherectomy
Technology | Atherectomy Devices | September 29, 2017
Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the...
Ra Medical Systems Receives FDA Clearance for New Peripheral Artery Disease Treatment
Technology | Atherectomy Devices | May 30, 2017
The U.S. Food and Drug Administration (FDA) announced that it has granted market clearance to Ra Medical Systems for...
CSI recall for saline pump on its atherectomy system
News | Atherectomy Devices | April 19, 2017
Cardiovascular Systems Inc. (CSI) announced April 18 it had initiated a voluntary recall of its 7-10014 Saline Infusion...
Cardiovascular Systems Inc., CSI, ECLIPSE clinical trial, Diamondback 360 Coronary Orbital Atherectomy System, first subject enrolled
News | Atherectomy Devices | April 04, 2017
Cardiovascular Systems Inc., in partnership with the Cardiovascular Research Foundation (CRF), announced the first...
CSI, LIBERTY 360 Study, ISET 2017, six-month data, lower extremity PAD
News | Atherectomy Devices | February 08, 2017
February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a
Avinger, VISION Study, two-year outcomes, LINC, Lumivascular technology, Pantheris, OCT-guided atherectomy
News | Atherectomy Devices | February 03, 2017
Avinger Inc. recently announced positive two-year clinical data from the pivotal VISION study of the company’s...
Overlay Init